Skip to main content Back to Top


Chloroquine Phosphate Tablets

Products Affected - Description

    • Chloroquine oral tablet, Sun Pharma, 250 mg, bottle, 50 count, NDC 63304-0460-50 - discontinued

Reason for the Shortage

    • Rising has product available.
    • Sun Pharma discontinued chloroquine tablets.

Available Products

    • Chloroquine tablet, Rising Pharmaceuticals, 250 mg, 50 count, NDC 64980-0177-50
    • Chloroquine tablet, Rising Pharmaceuticals, 500 mg, 25 count, NDC 64980-0178-02

Estimated Resupply Dates

    • Rising has chloroquine phosphate 250 mg and 500 mg tablets readily available.

Implications for Patient Care


Updated July 14, 2021 by Megan Dryer, PharmD. Created March 9, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.